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BACKGROUND AND PURPOSE
Predicting the risk of drug-induced adverse psychiatric effects is important but currently not possible in non-human species. We
investigated whether the affective bias test (ABT) could provide a preclinical method with translational and predictive validity.
EXPERIMENTAL APPROACH
The ABT is a bowl-digging task, which quantiﬁes biases associated with learning and memory. Rats encounter independent
learning experiences, on separate days, under either acute manipulations (e.g. pro-depressant vs. control) or different absolute
reward values (e.g. high vs. low). A bias is observed during a preference test when an animal’s choices reﬂect their prior experi-
ence. We investigated the effects of putative pro-depressant drug treatments following acute or chronic administration on the
formation of an affective bias or reward-induced positive bias respectively.
KEY RESULTS
The immunomodulators LPS (10 μg·kg1), corticosterone (10 and 30 mg·kg1) and IFN-α (100 U·kg1) induced a negative af-
fective bias following acute treatment. Tetrabenazine (1 mg·kg1) also induced a negative bias, but no effects were observed with
varenicline, carbamazepine or montelukast. Chronic treatment with IFN-α (100 U·kg1) and retinoic acid (10 mg·kg1) impaired
the formation of a reward-induced positive bias but did not alter sucrose preference test (SPT).
CONCLUSIONS AND IMPLICATIONS
The ABT has the potential to provide a novel approach to predict pro-depressant risk in a non-human species. Negative biases
induced by acute treatment in the standard version of the task may also predict longer-term effects on reward processing as
shown by the deﬁcit in reward-induced positive bias following chronic treatment, an effect distinct from anhedonia in the SPT.
LINKED ARTICLES
This article is part of a themed section on Pharmacology of Cognition: a Panacea for Neuropsychiatric Disease? To view the other
articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.19/issuetoc
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Introduction
A number of commonly prescribed, non-psychotropic medi-
cations have been associated with serious neuropsychiatric
adverse events such as depression, anxiety and suicidal idea-
tion (Patten and Love, 1994; Celano et al., 2011). While some
of these drugs are known to interact with the immune sys-
tem, such as immunosuppressants and antiviral medications,
others spanning a wide range of pharmacological classes have
also been observed to increase the risk of these psychiatric
side effects; these include anti-epileptics, cannabinoid
receptor 1 (CB1 receptor )antagonists/inverse agonists
and nicotinic ACh receptor partial agonists. Since much
of the information regarding these side effects is derived
during late stage clinical trials, or from case reports emerging
after the drugs have been licensed for treatment (Reith and
Edmonds, 2007), many of them have been issued with a black
box warning for neuropsychiatric side effects by the Food and
Drug Administration (FDA, 2008) or have been withdrawn
from themarket (FDA, 2009). Amajor obstacle for drug devel-
opment is the lack of translational preclinical tests with good
predictive validity for pro-depressant drug effects. The cur-
rent methods used to assess depression-like behaviour in
non-human species utilize models of behavioural despair
and anhedonia such as the forced swim test, tail suspension
test and sucrose preference test (SPT). These methods are pre-
dictive of antidepressant efﬁcacy, particularly for drugs acting
via monoaminergic mechanisms, but these approaches have
not provided reliable data for drugs from other classes
(Tzavara et al., 2003; Wallace-Boone et al., 2008). However,
recent advances in the use of cognitive neuropsychological
testing in human depression research have provided a new
opportunity for developing translational methods in labora-
tory animals. Studies investigating emotion-induced changes
in cognitive processes such as learning, memory and
decision-making have shown that both depressed patients
and those with a vulnerability to depression exhibit negative
affective biases (Mathews and MacLeod, 2005; Leppänen,
2006; Elliott et al., 2011; Roiser et al., 2012). For example, pa-
tients withmajor depression show reduced recall of positively
valenced words (Harmer et al., 2009b), as well as a reduced
recognition of happy facial expressions (Joormann and
Gotlib, 2006). Importantly, pro-depressant manipulations
have been shown to induce a negative shift in affective pro-
cessing in otherwise healthy volunteers (Horder et al., 2009).
The induction of negative affective bias may therefore rep-
resent an early indicator of increased risk for depression,
and the use of preclinical assays to detect drug-induced
negative biases may provide an effective early screen for
mood-related side effects.
The development of behavioural tasks to investigate affec-
tive biases in animals has progressed signiﬁcantly in recent
years, with studies being conducted in a number of non-
human species (see Hales et al., 2014 for a review). In particu-
lar, the affective bias test (ABT) has been used in rats to test for
biases in reward learning and memory induced by different
affective states (Stuart et al., 2013). Initial validation experi-
ments showed that acute changes in affective state at the time
of learning a substrate–reward association biases subsequent
choice behaviour during a preference test. It has been demon-
strated that a positive affective state, or acute antidepressant
treatment, induced a bias towards the substrate–reward
pairing learned following the positive manipulation (Stuart
et al., 2013; Refsgaard et al., 2016). Conversely, a negative af-
fective state (e.g. induced by psychosocial stress) resulted in
a bias away from the substrate–reward pairing learned during
the negative manipulation (Stuart et al., 2013).
This present work aims to test the predictive validity of
the ABT in detecting acute drug-induced negative affective
biases associated with putative pro-depressant drugs. Our ini-
tial set of studies are designed to test the effects of drugs that
interfere with the immune system, by testing two immuno-
modulators that are used in behavioural research to induce
a depression-like phenotype in animals: the stress hormone
corticosterone (Johnson et al., 2006) and the pro-
inﬂammatory mediator LPS (Kubera et al., 2013). We then
tested the effects of IFN-α, a drug that has been shown to
increase the risk for depression and suicidality in patients
undergoing immunotherapy (Raison et al., 2005). Following
these, we then investigated the effects of a number of drugs
with distinct pharmacological mechanisms that have been
associated, to varying degrees, with an increased risk of
depression in the clinic: tetrabenazine [used as an off-label
treatment for chorea in Huntington’s disease (Jankovic and
Beach, 1997; Kenney et al., 2006)], varenicline [developed as
an aid for smoking cessation (FDA, 2009)], carbamazepine
[an anticonvulsant treatment for epilepsy (Mula and Sander,
2007)] and montelukast [a leukotriene receptor antag-
onist used in the treatment of chronic asthma (Manalai
et al., 2009)]. In order to evaluate the impact of long term
treatment with pro-depressant drugs, we also use a modiﬁed
version of the ABT that allows us to investigate the effects of
chronic drug treatments on reward-induced positive bias. In
this version of the assay, animals are trained to associated
one substrate with a higher value reward which, during
the preference test, induces a bias towards that substrate.
We hypothesized that impairments in reward processing,
as seen in human depression (see Pizzagalli, 2014 for re-
view), may be reﬂected as a blunted response in this assay
in animals in a putative negative affective state.
Methods
Animals
One cohort of 16 male Lister-hooded (LH) rats (~300–350 g,
Harlan, UK) was used to test corticosterone, carbamazepine
and varenicline. Two cohorts of 16 male Sprague Dawley
(SD) rats (~310–360 g, Charles River, UK) were used in all
other studies. Both strains have previously been shown to re-
spond in a similar manner in the ABT when tested using phar-
macological and psychosocial manipulations (Stuart et al.,
2013: Hinchcliffe et al., 2017). Our early work used LH rats,
but there is some evidence that the more commonly used
SD strain is more sensitive to stress (Deutsch-Feldman et al.,
2015), and so, most of the studies moved to using this strain.
The N numbers were based on previous studies and power es-
timates with α = 0.05 and β = 0.8 (Stuart et al., 2013). All ani-
mals were housed in pairs under temperature-controlled
conditions and a 12:12 h light–dark cycle (lights off at
0700 h). They weremaintained at approximately 90% of their
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free-feeding weight by restricting access to laboratory chow
(Purina, UK) to ~18 g per rat per day. Water was provided ad
libitum. All behavioural testing was carried out between
0900 and 1700 h during the animals’ active phase. All proce-
dures received ethical approval from the UK Home Ofﬁce and
were conducted in adherence to the regulations of the 1986
Animals (Scientiﬁc Procedures) Act and EU Directive
2010/63/EU. Animal studies are reported in compliance with
the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and
Lilley, 2015).
The affective bias test
General protocol. The rats were habituated to a 40 × 40 cm
Perspex test arena and trained to dig in two ceramic bowls
(10 cm diameter, 5 cm apart) ﬁlled with sawdust to obtain a
quantity of food pellets (45 mg rodent tablet, TestDiet;
Sandown Scientiﬁc, UK). Digging training was complete
once each rat was able to ﬁnd the pellets on 12 consecutive
trials within 20 s for each trial. Once trained to dig in
sawdust, animals underwent a discrimination session
consisting of discrete trials where the animal was placed
into the test arena and allowed to approach and explore
two bowls: one ‘rewarded’ substrate and one ‘blank’
unrewarded substrate. Once the animal started to dig in
one bowl (i.e. directed the nose below the surface of the
substrate), the other bowl was removed by the experimenter,
the latency to dig recorded and the trial recorded as either
correct (rewarded substrate) or incorrect (blank substrate). If
the animal failed to dig within 20 s, the trial was recorded as
an omission. Animals were run until they completed six
consecutive correct trials, within a maximum of 20 trials.
One SD rat failed to complete the bowl digging training and
was therefore excluded from drug testing.
Dose–response studies. Each study followed a standard
protocol of four pairing sessions followed by a preference
test session on the ﬁfth day (Figure 1A). Each pairing session
followed the same protocol as the discrimination session
described above. All studies used a within-subject design
wherein each animal learnt to associate two different
digging substrates (A or B) with a food pellet reward during
pairing sessions. These pairing sessions were carried out on
separate days following either drug treatment or vehicle. The
pairing sessions were carried out on days 1–4 (Figure 1A),
and on the ﬁfth day, the rats were presented with both
reinforced substrates for the ﬁrst time and their choices over
30 trials recorded. For the preference test trials, a single
pellet was placed in one of the bowls using a random
reinforcement protocol such that there was a 1 in 3
probability for each substrate. Trials were run as described
above, and an animal’s latency to dig and choice of substrate
(A or B) was recorded. In all studies, substrate, pairing
session and treatment (drug or vehicle) were fully counter-
balanced for each week of the study. The drug doses were
administered according to a fully randomised Latin square
design with all animals receiving all treatments by the end
of the study. Results from the preference test day were
recorded as number of choices for the vehicle-paired
substrate versus the number of choices for the drug-paired
substrate and were used to calculate a % choice bias value
for further analysis.
Figure 1
Overview of the ABT protocols. (A) ABT protocol to test drug-induced affective bias. Animals undergo pairing sessions in the presence of the test
drug (e.g. day 1 and 3) versus vehicle treatment (e.g. day 2 and 4). Drug-induced affective bias is then evaluated in a preference test (day 5) in the
absence of drug treatment. (B) Modiﬁed ABT protocol to test effects of chronic drug treatment on reward-induced positive bias. Animals are
treated once a day with drug (IFN-α or retinoic acid) or vehicle for 14 days. Each animal then undergoes pairing sessions where one substrate
is paired with a single food pellet reward (e.g. substrate A on day 1 and 3), and the other paired with two food pellets (e.g. substrate B on day
2 and 4). Reward-induced affective bias is then evaluated in a preference test (day 5) with both substrates randomly reinforced with 1 pellet. Con-
summatory anhedonia is then assessed in a SPT. Chronic drug treatment is continued throughout the study period.
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Chronic drug studies. Animals were treated with drug/
vehicle once daily for 14 days. Each animal then
underwent pairing sessions as previously described;
however, one substrate (A or B) was paired with a single
food pellet reward, and the other paired with two food
pellets (see Figure 1B). Preference test trials were run with a
single pellet using the random reinforcement protocol.
Drug treatment was continued throughout the week of
pairing sessions, with treatment being administered at
~1600–1700 h each day, after pairing sessions were complete.
Sucrose preference test
The protocol for the SPT was adapted from Willner et al.
(1987). Seventy-two hours before the ﬁrst test, rats were
given access to one bottle of water and one bottle of 1%
sucrose solution in their home cage for 48 h to avoid
neophobia during the test. The position of the sucrose
solution was counterbalanced across cages and test session.
The sucrose solution was then removed and replaced with
water until the test day. On test days, animals were
deprived of water for 4 h and moved into individual clean
cages for 30 min to habituate. Sucrose preference was then
determined by a 1 h exposure to two identical bottles ﬁlled
with either 1% sucrose solution or water. The position of
the bottles was counterbalanced across tests using a
pseudorandom method. Sucrose preference was deﬁned as
the ratio of the volume of sucrose versus water consumed
during the test.
Data and statistical analysis
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015). All studies were performed with the
experimenter blind to drug treatment until the end of the
study. Choice bias was calculated based on the number of
choices made for the treatment-paired substrate versus the to-
tal number of trials (treatment-paired substrate + control-
paired substrate). A value of 50 was then subtracted from
the choice bias score to give a % choice bias where a bias to-
wards the treatment-paired substrate gave a positive value
and a bias towards the control-paired substrate gave a nega-
tive score. The % choice bias data from dose–response exper-
iments were analysed using a repeatedmeasures ANOVAwith
DOSE as factor, whilst data from chronic drug studies used an
unpaired t-test comparing drug versus vehicle treatment
groups. Post hoc analysis for each dose/treatment group used
a one-sample t-test against a theoretical mean of 0% choice
bias where 0% is equivalent to 15 choices for the treatment-
paired substrate and 15 choices for the control-paired sub-
strate. Latency and trials to criterion were recorded during
pairing sessions to determine whether there were any non-
speciﬁc effects of treatment, for example, sedation and an-
orexia. Analysis of these data was made using a paired t-test
comparing treatment versus control for the pairing sessions.
Sucrose preference data between drug-treated and vehicle-
treated groups were analysed using an unpaired t-test.
P < 0.05 was considered to indicate statistical signiﬁcance.
Statistical analyses were performed using SPSS Statistics 23
and graphs created using GraphPad Prism v7.
Drugs
Carbamazepine, corticosterone, tetrabenazine, rat recombi-
nant IFN-α, LPS and 13-cis retinoic acid were purchased from
Sigma Aldrich (UK) and varenicline was purchased from
Abcam (UK). Montelukast was purchased from the Bristol
Royal Inﬁrmary Pharmacy (UK). Carbamazepine, corticoste-
rone, retinoic acid and varenicline were dissolved in a 10%
DMSO, 20% cremaphor and 70% saline mix. Tetrabenazine
was dissolved in a 20% DMSO and 80% saline mix at pH 2.0
which was then adjusted to pH 5.5 for dosing. IFN-α and
LPS were resuspended in saline and stocks stored at 20 °C
until use. Montelukast was dissolved in saline and adjusted
to pH 7.4 for dosing. The saline-based solutions in which
the test drugs were dissolved were administered by the same
route and pretreatment procedure to provide a matched
vehicle condition in each study. All drugs were adminis-
tered at a dose volume of 1 mL·kg1 i.p. using a modiﬁed
handling technique to minimize stress (Stuart and
Robinson, 2015). With the exception of montelukast
which was administered 20 min before the ABT pairing
sessions, all other drugs were given 30 min prior to the
session. For the dose–response studies, the range of doses
and pretreatment times used were based on previous
behavioural studies in rodents [corticosterone:
0–30 mg·kg1 (Johnson et al., 2006); IFN-α: 0–100 U·kg1
(Kentner et al., 2006); tetrabenazine: 0–1 mg·kg1 (Nunes
et al., 2013); varenicline: 0–1 mg·kg1 (Rollema et al.,
2009); carbamazepine: 0–30 mg·kg1 (Redrobe and Bourin,
1999); and montelukast: 0–3 mg·kg1 (Ihaku et al., 1999)].
The dose range for LPS (0–10 μg·kg1) was chosen based
on pilot data showing locomotor impairment at higher
doses, so the maximum dose tested was 10 μg·kg1
(Supporting Information Figure S1). For the chronic studies,
the dose of IFN-α (100 U·kg1) was selected as a result of the
acute dose–response data as well as screening for overt
sickness behaviour (Supporting Information), and the
retinoic acid dose (10 mg·kg1) was selected based on results
from our previous work in the ABT (Stuart et al., 2013).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data
from the IUPHAR/BPS Guide to PHARMACOLOGY
(Southan et al., 2016), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2015/16 (Alexander
et al., 2015a,b).
Results
Effects of immunomodulators on affective bias
in the ABT
In an initial dose–response study with the pro-inﬂammatory
agent LPS, acute treatment tended to induce a dose-
dependent negative affective bias in rats (F3,42 = 2.67,
P = 0.06, n = 15; Figure 2A). A single-dose study was subse-
quently carried out with a higher concentration of 10 μg·kg1
and was found to induce a signiﬁcant negative bias (one sam-
ple t-test: t14 = 3.3, P < 0.05 vs. 0% choice bias). This dose did
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not have any effect on latency in the ABT (a food-motivated
task) but did reduce activity in a spontaneous test of locomo-
tor activity (Supporting information). Acute treatment with
the stress hormone corticosterone induced a negative
affective bias at 10 and 30 mg·kg1 (F2,30 = 5.52,
P < 0.05, n = 16; Figure 2B). The highest dose also
increased the number of trials required to reach criterion
in pairing sessions compared to VEH (Supporting Informa-
tion Table S1). Similarly, acute treatment with IFN-α
induced a negative affective bias at a dose of 100 U·kg1
(F2,28 = 3.91, P < 0.05, n = 15; Figure 2C). None of the
immunomodulators tested had any effect on omissions
during the pairing sessions.
Effects of putative pro-depressant drugs on
affective bias in the ABT
Tetrabenazine induced a negative affective bias in rats at a
dose of 1 mg·kg (F3,42 = 3.28, P < 0.05, n = 15; Figure 3A),
and whilst varenicline tended to induce a negative bias, the
main effect was not statistically signiﬁcant (Figure 3B).
Varenicline was repeated with a single, higher dose of
1 mg·kg1; however, this also failed to induce a signiﬁcant
bias. Carbamazepine tended to induce a negative bias at the
higher dose used; however, the effect did not reach statistical
signiﬁcance (F3,45 = 2.36, P = 0.084, n = 16; Figure 3C). The
test was not repeated with a higher dose (as with varenicline),
as animals showed an increase in trial latency during pairing
sessions following carbamazepine treatment, suggesting a
sedative effect of the drug (Supporting Information
Table S1). No overall effect was found with the leukotriene
receptor antagonist, montelukast (Figure 3D). None of the
drugs tested had any effects on omissions during the
pairing sessions.
Effects of chronic pro-depressant drug treatment
on reward-induced positive bias and anhedonia
Since IFN-αwas shown to induce a negative bias when admin-
istered acutely (Figure 1C), it was then used to investigate the
longer-term effects of chronic treatment on reward-induced
positive bias in the ABT, as well as anhedonia in the SPT. Data
from the ABT showed that whilst vehicle-treated animals
demonstrated a positive bias towards the two pellet-paired
substrate (Figure 4A, panel i), this effect was absent in animals
treated for 14 days with IFN-α (unpaired t-test: t14 = 3.04,
P < 0.05, n = 8 per group). No effect was observed in the
SPT, with both treatment groups showing a preference for
the sucrose solution (Figure 4A, panel ii). These results were
replicated with retinoic acid, a drug that we have previously
shown to induce a negative affective bias when given acutely
(Stuart et al., 2013). Animals treated for 14 days with retinoic
acid show a deﬁcit in reward-induced positive bias (unpaired
t-test: t13 = 2.84, P < 0.05,vehicle: n = 7, retinoic acid: n = 8;
Figure 4B, panel i), but no difference in sucrose preference
when compared to control animals (Figure 4B, panel ii).
Neither IFN-α nor retinoic acid affected response latencies,
trials to criterion or omissions during pairing sessions
(Supporting Information Table S2).
Figure 2
The effect of acute treatment with immunomodulating agents on affective bias in the ABT. Negative biases were observed following acute treat-
ment with (A) LPS (n = 15), (B) corticosterone (n = 16) and (C) IFN-α (n = 15). Data are shown as the mean % choice bias for the drug-paired
substrate ± SEM, *P < 0.05 (one sample t-test vs. theoretical mean of 0% bias). Dotted line indicates independent experiments where a higher
dose was tested following the dose–response study.
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Figure 3
The effects of putative pro-depressant drugs on affective bias in the ABT. (A) Tetrabenazine (n = 15) induced a negative affective bias, but only
limited effects were observed with (B) varenicline (n = 16) and (C) carbamazepine (n = 16). (D) No effect was observed with montelukast
(n = 15). Data are shown as the mean % choice bias for the drug-paired substrate ± SEM, *P < 0.05 (one sample t-test vs. theoretical mean of
0% bias). Dotted line indicates independent experiments where a higher dose was tested following the dose–response study.
Figure 4
The effect of chronic treatment with putative pro-depressant drugs on reward-induced positive bias in the ABT and anhedonia in the SPT. Whilst
vehicle (VEH)-treated animals demonstrated a positive bias for the two-pellet paired substrate, animals chronically treated with either (A, panel i)
IFN-α (n = 8 per group) or (B, panel i) retinoic acid (VEH: n = 7, retinoic acid: n = 8) failed to show a bias. (A, panel ii, B, panel ii) Sucrose preference
was not affected by either drug. Data are shown as mean % ± SEM, *P < 0.05 (one sample t-test vs. theoretical mean of 0% bias), #P < 0.05
(independent samples t-test vs. VEH group).
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Discussion
These ﬁndings build on our previous work suggesting that the
ABT provides a novel translational approach to studying pro-
depressant drug effects and predicting adverse psychiatric
side effects in a non-human model. Consistent with our pre-
vious observations (Stuart et al., 2013), drugs which have
pro-depressant effects in patients were observed to induce
negative affective biases following acute administration in
our ABT. The possible implications for these ﬁndings in terms
of animal models for psychiatry research and safety phar-
macology are discussed below. As well as our studies using
acute drug manipulations, we have also found that drugs
which induce an acute negative affective bias will also in-
duce deﬁcits in reward-induced positive bias following
chronic treatment. We propose that this deﬁcit may involve
similar neurobiological substrates to the anticipatory reward
deﬁcit observed in depression (Sherdell et al., 2012) and dis-
cuss the implications for both depression research and
safety evaluation.
Effects of immunomodulators on negative
affective biases in the ABT
Our initial studies aimed to test whether an acute effect of
immunomodulation in the ABT is predictive of the risk for
depressive symptoms associated with chronic illness and
long-term immunotherapy. Administration of the pro-
inﬂammatory endotoxin, LPS is often used as a model of
cytokine-induced sickness behaviour, inducing depression-
like behaviours in animals that are comparable to those
observed in chronic stress (Yirmiya, 1996; Kubera et al.,
2013). Similarly, high doses of the stress hormone cortico-
sterone have been shown to reliably increase immobility
in the forced swim test and reduce sucrose consumption
in the SPT (Gregus et al., 2005; Johnson et al., 2006). We
observed that when administered acutely, both LPS and
corticosterone induced a negative affective bias in rats. It
should be noted that the dose of LPS that was effective in
the ABT also reduced spontaneous locomotor activity,
although it did not have any effects on choice latency dur-
ing the ABT, suggesting that the measures of motor
function in the two assays are not the same. The highest
dose of corticosterone increased the number of trials re-
quired in the pairing sessions; nevertheless, all animals
were able to reach the same criterion of correct choices
within the maximum allowed trials. This suggests that the
corticosterone-induced negative bias is unlikely to be a re-
sult of a memory deﬁcit, since the animals are still able
to form the appropriate substrate–reward association. We
also showed that acute treatment with IFN-α, a drug that
is well-documented to induce depressive symptoms in
20–50% of patients (Raison et al., 2005), induced a similar
negative bias which was also dose-dependent. We observed
that animals formed a negative bias away from the experi-
ence learned following drug treatment relative to the expe-
rience learned under control conditions, suggesting that
the relative value of the experience has been reduced,
resulting in a negative choice bias. Together, our ﬁndings
are consistent with our prediction that risk factors for de-
pression such as immune stress and medications that
modulate the immune system, share similar effects on
reward-related learning and memory in the ABT.
The development of major depressive disorders in physi-
cally ill patients with no previous history of mental disorders
is well documented (for review, see Evans et al., 2005), and
some of the mechanisms that might be responsible for
inﬂammation-mediated sickness and depression have now
been elucidated (for review, see Dantzer et al., 2008). Chronic
activation of the immune system, including immunotherapy,
causes a profound reduction in circulating levels of the 5-HT
precursor, tryptophan, which correlates with patients’ de-
pression scores (Capuron et al., 2002, 2003). Interestingly,
tryptophan depletion has been found to induce a negative
bias in the processing of affective information in healthy vol-
unteers (Murphy et al., 2002; Evers et al., 2006; van der Veen
et al., 2007). It is therefore possible that the negative biases
observed in the ABT following acute immunomodulation
may be, at least in part, mediated through changes in the se-
rotonergic system.
Effects of drugs with purported pro-depressant
risk in clinical populations
Although concerns regarding pro-depressant effects and
increased suicidal ideation and behaviours have been
reported for a number of different prescription drugs, em-
pirical data are limited. This has partly arisen due to a lack
of valid animal models and the difﬁculty in demonstrating
clear causality when studying clinical populations. In the
ABT, we observed a negative bias following treatment with
tetrabenazine but no clear effects for the other drugs
tested. Depression occurs in up to 15% of patients
receiving tetrabenazine treatment for Huntington’s disease
(Jankovic and Beach, 1997; Kenney et al., 2006), and since
it acts as an inhibitor of the vesicular monoamine trans-
porter, VMAT2, it has similar monoamine depleting effects
as the known pro-depressant drug, reserpine (Quinn et al.,
1959; Zheng et al., 2006). Neither varenicline, carbamaze-
pine nor montelukast induced a bias in the ABT
although at higher doses, both varenicline and carbamaze-
pine did exhibit mean values which were negative. Con-
cerns were raised by the FDA (2009) over the use of
varenicline, a nicotinic acetylcholine receptor (α4
subunit) partial agonist, as a smoking cessation aid, due
to its association with adverse neuropsychiatric effects.
However, its lack of overall effect in the ABT is consistent
with a more recent systematic review and meta-analysis of
the effects of varenicline that found no evidence for an
increase in depression or suicidal behaviour in patients
(Thomas et al., 2015). Similarly, carbamazepine, an anti-
convulsant drug, and montelukast, a leukotriene receptor
antagonist used for chronic asthma, failed to induce a
signiﬁcant affective bias in the ABT. These results appear
to reﬂect the clinical picture where, despite individual case
reports of negative emotion-related side effects of these
drugs, they have not overall been found to increase
depressive behaviours in patients (Philip et al., 2009;
Andersohn et al., 2010).
An important issue in the ﬁeld of drug safety research is
that the incidence of adverse neuropsychiatric side effects as-
sociated with chronic drug treatments are not well deﬁned,
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and symptoms are seen only in a sub-population of patients.
Therefore, there is a need not only for methods that predict
risk of mood-related side effects but also to understand why
certain drugs cause these effects and why only a sub-
population of patients appear to be at risk. Recently, studies
suggest that drugs such as tetrabenazine and varenicline
may exacerbate depressive symptoms in patients with a pre-
existing psychiatric illness (Kenney et al., 2006; Thomas
et al., 2015). Considering the hypothesis that negative affec-
tive biases play a key role in the development of persistent
negative mood states (Harmer et al., 2009a; Robinson and
Roiser, 2016), it is plausible that an increased sensitivity to
negative affective bias may underlie individual vulnerability
to drug-induced depression.
Chronic pro-depressant drug treatment impairs
reward-induced positive bias, independent of
anhedonia in the SPT
Using a modiﬁed version of the ABT, we are able to investi-
gate the effects of chronic manipulations on reward-related
learning and memory and their effects on subsequent antici-
pation of reward. Animals make a decision about which
substrate–reward cue to select in the preference test based
on their prior experience of the association. We propose that
the loss of reward-induced positive bias reﬂects a failure to ap-
propriately anticipate the greater value of the substrate paired
with the higher value reward during learning. Under normal
conditions, rats demonstrate a positive bias towards a sub-
strate that had previously been paired with a higher value of
reward. This is consistent with a number of other studies in
animal behaviour that have similarly shown that rodents will
learn to associate a cue with a higher value reward and subse-
quently demonstrate a preference for that cue over one that
predicts a reward of lower magnitude (Vogel et al., 1968;
Lattal and Gleeson, 1990; Giertler et al., 2003). We have been
able to show that two drugs that induce negative bias in the
ABT following acute treatment, IFN-α and retinoic acid
(Stuart et al., 2013), impaired this reward-induced positive
bias following 14 days of treatment. Interestingly, our data
show that this occurs in the absence of a reduction in sucrose
preference, replicating ﬁndings from other groups that fail to
show an effect of chronic IFN-α and retinoic acid treatment in
the SPT (De La Garza et al., 2005; Ferguson et al., 2005). It has
been shown previously that sub-chronic PCP treatment
causes an impairment in reward-induced positive bias in rats,
without affecting measures of consummatory anhedonia
(Lydall et al., 2010; Sahin et al., 2016). Together with our
current data, these ﬁndings suggest that the reward deﬁcits
observed in the ABT are independent of the anhedonia as
measured by the SPT.
While tasks like the SPT are able to quantify consumma-
tory aspects of reward, and how animals experience pleasure
at the time of consumption, the deﬁcits in human depression
are not associated with a similar impairment (Berlin et al.,
1998; Dichter et al., 2010). Depression is more commonly as-
sociated with impairments in anticipation of reward, which
we propose represent an interaction between cues which pre-
dict reward, activation of memory processes and subsequent
recall of expected reward value, as well as motivation to ob-
tain the reward. Whilst various methods involving chronic
stress have been shown to decrease sucrose preference in
rodents (Willner et al., 1992), several researchers have been
unable to replicate these ﬁndings (Forbes et al., 1996; Harris
et al., 1997; Reid et al., 1997). These results from human and
animal studies suggest that the SPT is less suitable as an as-
sessment of anhedonia relevant to depressive disorders, and
we propose that our current work indicates that reward deﬁ-
cits as measured by the ABT may be more broadly associated
with pro-depressant effects. The ABT requires animals to use
their prior experiences of reward-associated stimuli to guide
their subsequent decision behaviour so may be able to tap
into the more complex interactions between valuation, pre-
diction and anticipation of reward that play a key role in
depression.
Conclusion
Overall, our data suggest that that ABT shows good predictive
validity for pro-depressant drug effects and allows us to inves-
tigate both the acute and chronic effects of drugs on reward-
related affective biases. Our results also suggest that the ABT
can be used to model the anticipatory reward deﬁcit observed
in depression. Studies designed to investigate the risk of pro-
depressant effects in animals, as a means to predict their ef-
fects in humans, are still limited. However, we show that
using an objective measure of reward-related symptoms pro-
vides the opportunity to develop animal models with greater
translational validity.
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